Impact of platinum-based and non-platinum chemotherapy on quality of life in non-small cell lung cancer: A narrative review
Abstract
Chemotherapy remains one of the main therapeutic options for patients with advanced non-small cell lung cancer (NSCLC), a disease that continues to contribute significantly to global cancer-related mortality. The selection of platinum-based or non-platinum chemotherapy regimens has important clinical implications, as these approaches differ not only in antitumor efficacy but also in their impact on patients’ health-related quality of life (HRQoL). This narrative review aimed to synthesize recent evidence regarding the effects of platinum-based and non-platinum chemotherapy on HRQoL among patients with NSCLC. Relevant studies published between 2020 and 2025 were identified through systematic searches of major scientific databases, including PubMed, Scopus, and Web of Science. The findings were narratively synthesized across commonly reported HRQoL domains using validated assessment instruments, such as the Functional Assessment of Cancer Therapy–Lung (FACT-L), the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Lung Cancer Module (QLQ-LC13), as well as the EQ-5D-5L. Overall, platinum-based chemotherapy was associated with better disease control but also with greater toxicity-related deterioration in physical and emotional functioning. In contrast, non-platinum regimens demonstrated improved tolerability and more stable HRQoL outcomes. These differences have important implications for shared clinical decision-making, particularly in patients with advanced disease for whom symptom relief and quality of life often represent primary treatment goals. This review highlights the need to integrate HRQoL considerations alongside clinical efficacy when individualizing chemotherapy strategies for patients with advanced NSCLC.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3):229-63.
https://doi.org/10.3322/caac.21834
Hendriks LE, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2024; 10(1):71.
https://doi.org/10.1038/s41572-024- 00551-9
Agbarya A, Shalata W, Addeo A, Charpidou A, Cuppens K, Brustugun OT, et al. Real-world journey of unresectable stage III NSCLC patients: current dilemmas for disease staging and treatment. J Clin Med 2022; 11(6):1738.
https://doi.org/10.3390/jcm11061738
Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health 2020; 17(19):6938. https://doi.org/10.3390/ijerph17196938
Saqib M, Din ZS, Zafar S, Munawar N, Nawaz R, Ahmed S, et al. Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations. Pers Med 2024; 21(6):385-400. https://doi.org/10.1080/17410541.2024.2391269
Tsvetkova D, Ivanova S. Application of approved cisplatin derivatives in combination therapy against different cancer diseases. Molecules 2022; 27(8):2466. https://doi.org/10.3390/molecules27082466
Takemoto S, Nakamura Y, Gyoutoku H, Senju H, Ogawara D, Ikeda T, et al. Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thorac Cancer 2019; 10(3):452
https://doi.org/10.1111/1759-7714.12958
Silveira FM, Wysocki AD, Mendez RDR, Pena SB, Santos EMD, Malaguti-Toffano S, et al. Impact of chemotherapy treatment on the quality of life of patients with cancer. Acta Paul Enferm 2021; 34:eAPE00583.
https://doi.org/10.37689/acta- ape/2021AO00583
Llamas-Ramos I, Alvarado-Omenat JJ, Rodrigo-Reguilón M, Llamas- Ramos R. Quality of life and side effects management in cancer treatment—a cross sectional study. Int J Environ Res Public Health 2023; 20(3):1708.
https://doi.org/10.3390/ijerph20031708
Koch M, Gräfenstein L, Karnosky J, Schulz C, Koller M. Psychosocial burden and quality of life of lung cancer patients: results of the EORTC QLQ-C30/QLQ-LC29 questionnaire and Hornheide screening instrument. Cancer Manag Res 2021; 13:6191-7.
https://doi.org/10.2147/CMAR.S314310
Yang QY, Zhu L, Liu HX, Zheng QS, Li LJ. Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer. Front Pharmacol 2022; 13:806728. https://doi.org/10.3389/fphar.2022.806728
Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S, et al. Outcome of weekly carboplatin– paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum– fluoropyrimidine-based treatment: a multicentre, retrospective review. Clin Oncol (R Coll Radiol) 2020; 32(2):121-30.
https://doi.org/10.1016/j.clon.2019.09.058
Koda Y, Kuribayashi K, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, et al. Irinotecan and gemcitabine as second-line treatment in patients with malignant pleural mesothelioma following platinum plus pemetrexed chemotherapy: a retrospective study. Oncology 2021; 99(3):161-8.
https://doi.org/10.1159/000510691
Chen Q, Ying S, Qin J, Zhang L. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer. Front Oncol 2024; 14:1384906. https://doi.org/10.3389/fonc.2024.1384906
Kozuki T, Nogami N, Hataji O, Tsunezuka Y, Seki N, Harada T, et al. Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Transl Lung Cancer Res 2020; 9(3):459-70. https://doi.org/10.21037/tlcr.2020.03.29
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non–small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 2020; 6(5):e196828.
https://doi.org/10.1001/jamaoncol.2019.6828
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev 2021; 2(12):e791-800.
https://doi.org/10.1016/S2666- 7568(21)00255-5
Yang JC, Mok TSK, Lu S, Nakagawa K, Yamamoto N, Shi YK, et al. Efficacy and safety of S-1 compared with docetaxel in elderly patients with advanced NSCLC previously treated with platinum-based chemotherapy: a subgroup analysis of the EAST- LC trial. JTO Clin Res Rep 2021; 2(3):100142.
https://doi.org/10.1016/j.jtocrr.2021.100142
Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H, et al. Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single- arm, phase 2 study. J Thorac Oncol 2023; 18(6):769-79.
https://doi.org/10.1016/j.jtho.2023.01.083
Yang JCH, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor–resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol 2024; 42(34):4029-39.
